|
Cardiovascular Pharmacology Concepts |
|
Electrolyte Supplements (Magnesium and Potassium) General Pharmacology Magnesium is an important ion in many enzymatic reactions, including cardiac Na+-K+-ATPase. Hypomagnesemia can inhibit this vital ion transport system and lead to cellular depolarization. Potassium ion plays an important role in membrane potentials, particularly in the resting membrane potential. It is also very important in the repolarization phase of cardiac pacemaker and non-pacemaker action potentials (phase 3). Therefore, hypomagnesemia (serum concentration <1.5 mg/dl) and hypokalemia (serum concentration <3.5 mg/dl; severe hypokalemia, <2.5 mg/dl) can precipitate cardiac arrhythmias, which include ventricular tachycardia and fibrillation, premature ventricular complexes, supraventricular tachycardias (e.g., Wolff-Parkinson-White Syndrome), atrial tachycardias, including flutter and fibrillation, and arrhythmias associated with digitalis toxicity. Specific Drugs For treating hypomagnesemia-associated arrhythmias, magnesium sulfate may by administered intravenously. Oral magnesium supplementation can be administered using magnesium gluconate, oxide or hydroxide salts. Potassium chloride may be administered intravenously or orally. |
|
DISCLAIMER: These materials are for educational purposes only, and are not a source of medical decision-making advice. © 2005-2008Ed Richard E. Klabunde, all rights reserved. |